{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:43Z","timestamp":1787962303127,"version":"build-2784847793"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,1,30]],"date-time":"2007-01-30T00:00:00Z","timestamp":1170115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti\u2013tumor necrosis factor (anti\u2010TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients who completed the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), a 24\u2010week, double\u2010blind study of adalimumab versus placebo in PsA, could elect to receive open\u2010label adalimumab, 40 mg subcutaneously every other week after week 24. Radiographs were obtained at week 48 and were read with radiographs obtained previously. Clinical and radiographic efficacy data were analyzed overall and in patient subsets. Safety data were collected over 48 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 48, patients from the adalimumab arm of ADEPT (n = 151) had achieved American College of Rheumatology 20% improvement (ACR20), ACR50, and ACR70 response rates of 56%, 44%, and 30%, respectively. Among those evaluated with the Psoriasis Area and Severity Index (PASI) (n = 69), PASI50, PASI75, PASI90, and PASI100 response rates (\u226550%, \u226575%, \u226590%, and 100% reduction in PASI scores, respectively) were 67%, 58%, 46%, and 33%, respectively (ACR and PASI response rates were analyzed using nonresponder imputation). Improvements in disability, as measured by the Disability Index of the Health Assessment Questionnaire (mean change in score \u20130.4) were sustained from week 24 to week 48. At week 24 and week 48, the mean changes from baseline in the modified total Sharp score were \u20130.1 and 0.1, respectively, for patients who received adalimumab for 48 weeks (n = 133), and 0.9 and 1.0, respectively, for patients who received placebo for 24 weeks followed by adalimumab for 24 weeks (n = 141). Adalimumab demonstrated clinical and radiographic efficacy regardless of whether patients were receiving methotrexate (MTX) at baseline. Adalimumab was generally safe and well tolerated through week 48.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adalimumab improved joint and skin manifestations, reduced disability, and inhibited radiographic progression over 48 weeks in patients with PsA who were participants in ADEPT. MTX use at baseline was not required for clinical or radiographic efficacy. Adalimumab had a good safety profile through week 48.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.22379","type":"journal-article","created":{"date-parts":[[2007,2,2]],"date-time":"2007-02-02T23:14:28Z","timestamp":1170458068000},"page":"476-488","source":"Crossref","is-referenced-by-count":238,"title":["Adalimumab for long\u2010term treatment of psoriatic arthritis: Forty\u2010eight week data from the adalimumab effectiveness in psoriatic arthritis trial"],"prefix":"10.1002","volume":"56","author":[{"given":"Dafna D.","family":"Gladman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H. S.","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Ory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee J.","family":"Perdok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948130"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_2_7_4_2","first-page":"127","article-title":"Psoriatic arthritis (PsA): an analysis of 220 patients","volume":"62","author":"Gladman DD","year":"1987","journal-title":"Q J Med"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.7.1511"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/30.4.245"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg384"},{"key":"e_1_2_7_8_2","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman DD","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg217"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.68"},{"key":"e_1_2_7_11_2","first-page":"675","article-title":"Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model","volume":"22","author":"Gladman DD","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.039826"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/000155598442809"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401021"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270403"},{"key":"e_1_2_7_17_2","first-page":"241","article-title":"Long\u2010term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome","volume":"2","author":"Abu\u2010Shakra M","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200106000-00005"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"e_1_2_7_20_2","first-page":"139","article-title":"Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis?","volume":"18","author":"Mader R","year":"1995","journal-title":"Clin Invest Med"},{"key":"e_1_2_7_21_2","first-page":"1957","article-title":"The use of sulfasalazine in psoriatic arthritis: a clinical experience","volume":"25","author":"Rahman P","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_2_7_26_2","first-page":"109","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: results for IMPACT 2 trial","volume":"64","author":"Van der Heijde D","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045658"},{"key":"e_1_2_7_29_2","first-page":"3","article-title":"Inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease PJ","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_7_32_2","first-page":"789","article-title":"The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales","volume":"9","author":"Fries JF","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280104"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030809"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018457"},{"issue":"1","key":"e_1_2_7_36_2","first-page":"391","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines","volume":"63","author":"Mease PJ","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_37_2","first-page":"561","article-title":"Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles","volume":"20","author":"Goldsmith CH","year":"1993","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21678"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013052"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.22379","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.22379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T02:07:34Z","timestamp":1696990054000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.22379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,30]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1002\/art.22379"],"URL":"https:\/\/doi.org\/10.1002\/art.22379","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,30]]}}}